The effects of vigabatrin on electrophysiology and visual fields in epileptics: A controlled study with a discussion of possible mechanisms

被引：29

作者：

Comaish I.F. ^{[1
]}

Gorman C. ^{[1
]}

Brimlow G.M. ^{[2
]}

Barber C. ^{[2
]}

Orr G.M. ^{[1
]}

Galloway N.R. ^{[1
]}

机构：

[1] Department of Ophthalmology, Queen's Medical Centre, Nottingham

[2] Department of Medical Physics, Queen's Medical Centre, Nottingham

来源：

Documenta Ophthalmologica | 2002年 / 104卷 / 2期

关键词：

Electrophysiology; Lateral inhibition; Oscillatory potentials; Vigabatrin; Visual fields;

D O I：

10.1023/A:1014603229383

中图分类号：

学科分类号：

摘要：

Purpose: To compare the visual electrophysiology and visual fields of patients taking vigabatrin to those of a control group of epileptics on other anti-epileptic drugs (AEDs). Methods: Fourteen epileptics treated with vigabatrin and 10 control patients treated with other AEDs underwent ERG and EOG. Goldmann visual fields were performed and analysed using standard software to measure areas contained within I4e isopters. Results: The cone and rod b-waves of the ERG, the oscillatory potential amplitudes and Arden indices were reduced in vigabatrin-treated subjects and the oscillatory potentials delayed. The Arden indices were reduced due to an increased dark trough. The areas contained within the I4e isopter of vigabatrin treated subjects were reduced compared to the control group and these areas correlated well with oscillatory potential amplitudes and b-wave amplitudes in the vigabatrin group only. Conclusions: The use of vigabatrin is associated with a reduction of the ERG cone b-wave amplitude and oscillatory potentials which correlates with visual field loss. The Arden ratio is reduced in subjects taking vigabatrin but may recover after cessation. However, visual loss may persist in the presence of a recovered EOG. These findings suggest further effects of the drug than those mediated by GABA receptors, and support the contention that the cause of the field loss may be at least in part due to retinal effects. Possible mechanisms are discussed.

引用

页码：195 / 212

页数：17

共 70 条

[41]

Roubertie A., Bellet H., Echenne B., Vigabatrin-associated retinal cone system dysfunction, Neurology, 51, (1998)

[42]

Hassel B., Johannessen C.U., Sonnewald U., Fonnum F., Quantification of the GABA shunt and the importance of the GABA shunt versus the 2-oxoglutarate dehydrogenase pathway in GABAergic neurons, J Neurochem, 71, 4, pp. 1511-1518, (1998)

[43]

Manev H., Pericic D., Sex differences in the turnover of GABA in the rat substantia nigra, J Neurol Transm, 70, 3-4, pp. 321-328, (1987)

[44]

Matern D., Lehnert W., Gibson K.M., Korinthenberg R., Seizures in a boy with succinic semialdehyde deficiency treated with vigabatrin (gamma-vinyl-GABA), J Inherit Metab Dis, 19, 3, pp. 313-318, (1996)

[45]

Medina-Kauwe L.K., Et al., Identification of a familial mutation associated with GABA-transaminase deficiency disease, Neurobiol Dis, 5, 2, pp. 89-96, (1998)

[46]

Jakobs C., Jaeken J., Gibson K.M., Inherited disorders of GABA metabolism, J Inherit Meb Dis, 16, 4, pp. 704-715, (1993)

[47]

Rivner M.H., Shamsnia M., Swift T.R., Trefz J., Roesel R.A., Carter A.L., Yanamura W., Hommes F.A., Kearns-Sayre syndrome and Complex II deficiency, Neurology, 39, 5, pp. 693-696, (1989)

[48]

Van Bemmelen F.J., Schouten M.J., Fekkes D., Bruinvels J., Succinic semialdehyde as a substrate for the formation of GABA, J Neurochem., 45, 5, pp. 1471-1474, (1985)

[49]

Manor D., Et al., The rate of turnover of cortical GABA from (1-<sup>13</sup>C)-glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA), Neurochem Res, 21, 9, pp. 1031-1041, (1996)

[50]

Halonen T., Pitkanen A., Riekkinen P.J., Administration of vigabatrin affects the levels of both inhibitory and excitatory amino acids in rat cerebrospinal fluid, J Neurochem, 55, 6, pp. 1870-1874, (1990)

← 1 2 3 4 5 6 7 →